Moonlake
IPONext-level Nanobody® therapies to elevate patient care
Zug, Switzerland · Founded 2021
- Headquarters
- Zug
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Last Round
- Series AJan 2021
- Rounds
- 1
About
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company registered in March 2021 as a Swiss stock corporation and headquartered in Zug, Switzerland. The company is developing Sonelokimab, a novel Nanobody that independently inhibits IL-17A and IL-17F to treat inflammatory diseases including hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). MoonLake listed on Nasdaq under ticker MLTX in April 2022 following a de-SPAC merger with Helix Acquisition Corp.
Summary
Moonlake is a Biotech company based in Zug, Switzerland, founded in 2021. Its most recent funding was a Series A round in Jan 2021. Investors include Hercules Capital, Cormorant Asset Management and Biotechnology Value Fund.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...